Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking
Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous...
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2022-08, Vol.40 (8), p.1270-1275 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1275 |
|---|---|
| container_issue | 8 |
| container_start_page | 1270 |
| container_title | Nature biotechnology |
| container_volume | 40 |
| creator | Shiakolas, Andrea R. Kramer, Kevin J. Johnson, Nicole V. Wall, Steven C. Suryadevara, Naveenchandra Wrapp, Daniel Periasamy, Sivakumar Pilewski, Kelsey A. Raju, Nagarajan Nargi, Rachel Sutton, Rachel E. Walker, Lauren M. Setliff, Ian Crowe, James E. Bukreyev, Alexander Carnahan, Robert H. McLellan, Jason S. Georgiev, Ivelin S. |
| description | Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.
B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery. |
| doi_str_mv | 10.1038/s41587-022-01232-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9378442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2700915859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-31778940f1552dc83790518fb585bf97a37a248959d8ea5155e3fc23bf082d3</originalsourceid><addsrcrecordid>eNp9kU1vFSEUhomxsbX6B1wYEjduUL4HNibtTf1ImjTxGreEYeBKnQtXmLlJ_fVyO7V-LLo6hPPwnvPyAvCC4DcEM_W2ciJUhzClCBPKKKKPwAkRXCIitXzczvjQJkIeg6e1XmOMJZfyCThmgnKimD4B40UI0UWfJjjE6vLelxuYA1yffV6jVf6KKEp-nood48-YNtCmKfZ5iL7CfbTwHDo_jrB453dTLrD6H7NPbiEHOMbNofRjdt_b3TNwFOxY_fO7egrW7y--rD6iy6sPn1Znl8jxjk-Ika5TmuNAhKCDU6zTWBAVeqFEH3RnWWcpV1roQXkrGuVZcJT1ASs6sFPwblHdzf3WD655a-ubXYlbW25MttH820nxm9nkvdGsU5zTJvD6TqDkZqdOZtu-pvm0yee5GiqZJJxoKhr66j_0Os8lNXOGdhjrFpDQjaIL5UqutfhwvwzB5hClWaI0LUpzG6U5bPHybxv3T35n1wC2ALW10saXP7MfkP0F78ap0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2700915859</pqid></control><display><type>article</type><title>Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking</title><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Shiakolas, Andrea R. ; Kramer, Kevin J. ; Johnson, Nicole V. ; Wall, Steven C. ; Suryadevara, Naveenchandra ; Wrapp, Daniel ; Periasamy, Sivakumar ; Pilewski, Kelsey A. ; Raju, Nagarajan ; Nargi, Rachel ; Sutton, Rachel E. ; Walker, Lauren M. ; Setliff, Ian ; Crowe, James E. ; Bukreyev, Alexander ; Carnahan, Robert H. ; McLellan, Jason S. ; Georgiev, Ivelin S.</creator><creatorcontrib>Shiakolas, Andrea R. ; Kramer, Kevin J. ; Johnson, Nicole V. ; Wall, Steven C. ; Suryadevara, Naveenchandra ; Wrapp, Daniel ; Periasamy, Sivakumar ; Pilewski, Kelsey A. ; Raju, Nagarajan ; Nargi, Rachel ; Sutton, Rachel E. ; Walker, Lauren M. ; Setliff, Ian ; Crowe, James E. ; Bukreyev, Alexander ; Carnahan, Robert H. ; McLellan, Jason S. ; Georgiev, Ivelin S.</creatorcontrib><description>Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.
B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/s41587-022-01232-2</identifier><identifier>PMID: 35241839</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/1647/2163 ; 631/1647/514/2254 ; 631/250/2152/2153 ; 631/250/255 ; ACE2 ; Agriculture ; Angiotensin ; Angiotensin-converting enzyme 2 ; Antibodies ; Antigens ; Bioinformatics ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Experiments ; Immunology ; Influenza ; Life Sciences ; Ligands ; Medical research ; Monoclonal antibodies ; Neutralizing ; Pandemics ; Peptidyl-dipeptidase A ; Proteins ; Receptors ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases</subject><ispartof>Nature biotechnology, 2022-08, Vol.40 (8), p.1270-1275</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</rights><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-31778940f1552dc83790518fb585bf97a37a248959d8ea5155e3fc23bf082d3</citedby><cites>FETCH-LOGICAL-c474t-31778940f1552dc83790518fb585bf97a37a248959d8ea5155e3fc23bf082d3</cites><orcidid>0000-0001-8451-9018 ; 0000-0002-0538-9647 ; 0000-0003-3991-542X ; 0000-0002-7038-5140 ; 0000-0003-4726-6132 ; 0000-0002-0342-4824 ; 0000-0002-6312-7696 ; 0000-0003-4351-125X ; 0000-0002-0049-1079 ; 0000-0001-5230-1532 ; 0000-0003-2571-1290 ; 0000-0003-0916-4098</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35241839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiakolas, Andrea R.</creatorcontrib><creatorcontrib>Kramer, Kevin J.</creatorcontrib><creatorcontrib>Johnson, Nicole V.</creatorcontrib><creatorcontrib>Wall, Steven C.</creatorcontrib><creatorcontrib>Suryadevara, Naveenchandra</creatorcontrib><creatorcontrib>Wrapp, Daniel</creatorcontrib><creatorcontrib>Periasamy, Sivakumar</creatorcontrib><creatorcontrib>Pilewski, Kelsey A.</creatorcontrib><creatorcontrib>Raju, Nagarajan</creatorcontrib><creatorcontrib>Nargi, Rachel</creatorcontrib><creatorcontrib>Sutton, Rachel E.</creatorcontrib><creatorcontrib>Walker, Lauren M.</creatorcontrib><creatorcontrib>Setliff, Ian</creatorcontrib><creatorcontrib>Crowe, James E.</creatorcontrib><creatorcontrib>Bukreyev, Alexander</creatorcontrib><creatorcontrib>Carnahan, Robert H.</creatorcontrib><creatorcontrib>McLellan, Jason S.</creatorcontrib><creatorcontrib>Georgiev, Ivelin S.</creatorcontrib><title>Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.
B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery.</description><subject>631/1647/2163</subject><subject>631/1647/514/2254</subject><subject>631/250/2152/2153</subject><subject>631/250/255</subject><subject>ACE2</subject><subject>Agriculture</subject><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme 2</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Bioinformatics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Experiments</subject><subject>Immunology</subject><subject>Influenza</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Medical research</subject><subject>Monoclonal antibodies</subject><subject>Neutralizing</subject><subject>Pandemics</subject><subject>Peptidyl-dipeptidase A</subject><subject>Proteins</subject><subject>Receptors</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU1vFSEUhomxsbX6B1wYEjduUL4HNibtTf1ImjTxGreEYeBKnQtXmLlJ_fVyO7V-LLo6hPPwnvPyAvCC4DcEM_W2ciJUhzClCBPKKKKPwAkRXCIitXzczvjQJkIeg6e1XmOMJZfyCThmgnKimD4B40UI0UWfJjjE6vLelxuYA1yffV6jVf6KKEp-nood48-YNtCmKfZ5iL7CfbTwHDo_jrB453dTLrD6H7NPbiEHOMbNofRjdt_b3TNwFOxY_fO7egrW7y--rD6iy6sPn1Znl8jxjk-Ika5TmuNAhKCDU6zTWBAVeqFEH3RnWWcpV1roQXkrGuVZcJT1ASs6sFPwblHdzf3WD655a-ubXYlbW25MttH820nxm9nkvdGsU5zTJvD6TqDkZqdOZtu-pvm0yee5GiqZJJxoKhr66j_0Os8lNXOGdhjrFpDQjaIL5UqutfhwvwzB5hClWaI0LUpzG6U5bPHybxv3T35n1wC2ALW10saXP7MfkP0F78ap0A</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Shiakolas, Andrea R.</creator><creator>Kramer, Kevin J.</creator><creator>Johnson, Nicole V.</creator><creator>Wall, Steven C.</creator><creator>Suryadevara, Naveenchandra</creator><creator>Wrapp, Daniel</creator><creator>Periasamy, Sivakumar</creator><creator>Pilewski, Kelsey A.</creator><creator>Raju, Nagarajan</creator><creator>Nargi, Rachel</creator><creator>Sutton, Rachel E.</creator><creator>Walker, Lauren M.</creator><creator>Setliff, Ian</creator><creator>Crowe, James E.</creator><creator>Bukreyev, Alexander</creator><creator>Carnahan, Robert H.</creator><creator>McLellan, Jason S.</creator><creator>Georgiev, Ivelin S.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8451-9018</orcidid><orcidid>https://orcid.org/0000-0002-0538-9647</orcidid><orcidid>https://orcid.org/0000-0003-3991-542X</orcidid><orcidid>https://orcid.org/0000-0002-7038-5140</orcidid><orcidid>https://orcid.org/0000-0003-4726-6132</orcidid><orcidid>https://orcid.org/0000-0002-0342-4824</orcidid><orcidid>https://orcid.org/0000-0002-6312-7696</orcidid><orcidid>https://orcid.org/0000-0003-4351-125X</orcidid><orcidid>https://orcid.org/0000-0002-0049-1079</orcidid><orcidid>https://orcid.org/0000-0001-5230-1532</orcidid><orcidid>https://orcid.org/0000-0003-2571-1290</orcidid><orcidid>https://orcid.org/0000-0003-0916-4098</orcidid></search><sort><creationdate>20220801</creationdate><title>Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking</title><author>Shiakolas, Andrea R. ; Kramer, Kevin J. ; Johnson, Nicole V. ; Wall, Steven C. ; Suryadevara, Naveenchandra ; Wrapp, Daniel ; Periasamy, Sivakumar ; Pilewski, Kelsey A. ; Raju, Nagarajan ; Nargi, Rachel ; Sutton, Rachel E. ; Walker, Lauren M. ; Setliff, Ian ; Crowe, James E. ; Bukreyev, Alexander ; Carnahan, Robert H. ; McLellan, Jason S. ; Georgiev, Ivelin S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-31778940f1552dc83790518fb585bf97a37a248959d8ea5155e3fc23bf082d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/1647/2163</topic><topic>631/1647/514/2254</topic><topic>631/250/2152/2153</topic><topic>631/250/255</topic><topic>ACE2</topic><topic>Agriculture</topic><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme 2</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Bioinformatics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Experiments</topic><topic>Immunology</topic><topic>Influenza</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Medical research</topic><topic>Monoclonal antibodies</topic><topic>Neutralizing</topic><topic>Pandemics</topic><topic>Peptidyl-dipeptidase A</topic><topic>Proteins</topic><topic>Receptors</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiakolas, Andrea R.</creatorcontrib><creatorcontrib>Kramer, Kevin J.</creatorcontrib><creatorcontrib>Johnson, Nicole V.</creatorcontrib><creatorcontrib>Wall, Steven C.</creatorcontrib><creatorcontrib>Suryadevara, Naveenchandra</creatorcontrib><creatorcontrib>Wrapp, Daniel</creatorcontrib><creatorcontrib>Periasamy, Sivakumar</creatorcontrib><creatorcontrib>Pilewski, Kelsey A.</creatorcontrib><creatorcontrib>Raju, Nagarajan</creatorcontrib><creatorcontrib>Nargi, Rachel</creatorcontrib><creatorcontrib>Sutton, Rachel E.</creatorcontrib><creatorcontrib>Walker, Lauren M.</creatorcontrib><creatorcontrib>Setliff, Ian</creatorcontrib><creatorcontrib>Crowe, James E.</creatorcontrib><creatorcontrib>Bukreyev, Alexander</creatorcontrib><creatorcontrib>Carnahan, Robert H.</creatorcontrib><creatorcontrib>McLellan, Jason S.</creatorcontrib><creatorcontrib>Georgiev, Ivelin S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiakolas, Andrea R.</au><au>Kramer, Kevin J.</au><au>Johnson, Nicole V.</au><au>Wall, Steven C.</au><au>Suryadevara, Naveenchandra</au><au>Wrapp, Daniel</au><au>Periasamy, Sivakumar</au><au>Pilewski, Kelsey A.</au><au>Raju, Nagarajan</au><au>Nargi, Rachel</au><au>Sutton, Rachel E.</au><au>Walker, Lauren M.</au><au>Setliff, Ian</au><au>Crowe, James E.</au><au>Bukreyev, Alexander</au><au>Carnahan, Robert H.</au><au>McLellan, Jason S.</au><au>Georgiev, Ivelin S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>40</volume><issue>8</issue><spage>1270</spage><epage>1275</epage><pages>1270-1275</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target–ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target–ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.
B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>35241839</pmid><doi>10.1038/s41587-022-01232-2</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8451-9018</orcidid><orcidid>https://orcid.org/0000-0002-0538-9647</orcidid><orcidid>https://orcid.org/0000-0003-3991-542X</orcidid><orcidid>https://orcid.org/0000-0002-7038-5140</orcidid><orcidid>https://orcid.org/0000-0003-4726-6132</orcidid><orcidid>https://orcid.org/0000-0002-0342-4824</orcidid><orcidid>https://orcid.org/0000-0002-6312-7696</orcidid><orcidid>https://orcid.org/0000-0003-4351-125X</orcidid><orcidid>https://orcid.org/0000-0002-0049-1079</orcidid><orcidid>https://orcid.org/0000-0001-5230-1532</orcidid><orcidid>https://orcid.org/0000-0003-2571-1290</orcidid><orcidid>https://orcid.org/0000-0003-0916-4098</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2022-08, Vol.40 (8), p.1270-1275 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9378442 |
| source | Nature; Alma/SFX Local Collection |
| subjects | 631/1647/2163 631/1647/514/2254 631/250/2152/2153 631/250/255 ACE2 Agriculture Angiotensin Angiotensin-converting enzyme 2 Antibodies Antigens Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Coronaviruses COVID-19 COVID-19 vaccines Experiments Immunology Influenza Life Sciences Ligands Medical research Monoclonal antibodies Neutralizing Pandemics Peptidyl-dipeptidase A Proteins Receptors Severe acute respiratory syndrome coronavirus 2 Viral diseases |
| title | Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T00%3A38%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficient%20discovery%20of%20SARS-CoV-2-neutralizing%20antibodies%20via%20B%20cell%20receptor%20sequencing%20and%20ligand%20blocking&rft.jtitle=Nature%20biotechnology&rft.au=Shiakolas,%20Andrea%20R.&rft.date=2022-08-01&rft.volume=40&rft.issue=8&rft.spage=1270&rft.epage=1275&rft.pages=1270-1275&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/s41587-022-01232-2&rft_dat=%3Cproquest_pubme%3E2700915859%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2700915859&rft_id=info:pmid/35241839&rfr_iscdi=true |